Transplanted Liver Cells May Provide Treatment Option for End-Stage Liver Disease
Five U.S. Centers Experimenting With Cell Transplant
Dec.1, 1999 (Chicago) -- Every year, 5,000 Americans receive new livers and a new lease on life. But for every person with end-stage liver disease, who is the lucky recipient of a new liver, three more are left waiting on the transplant list, and many of them will die waiting. Now an experimental technique being tested at several centers in the U.S. may offer hope those who wait for the gift of life: liver cell transplant.
Doctors at the Medical College of Virginia/Virginia Commonwealth University and the University of Nebraska Medical Center are using cells gathered from donor livers as either a bridge to transplant or bridge to recovery in patients with end-stage liver disease. The papers were presented at the 85th Scientific Assembly and Annual Meeting of the Radiological Society of North America.
Jaime Tisnado, MD, professor of cardiovascular and interventional radiology and surgery, Medical College of Virginia/Virginia Commonwealth University, Richmond, says his team has used the experimental procedure in 12 patients.
"One of the patients recovered with the infused cells alone and seven are alive awaiting whole organ transplant," Tisnado tells WebMD. The woman who recovered with just a cell transplant was in her mid-30s and had traumatic liver damage, probably from a drug reaction. "When we transplanted her she was bleeding out. The next morning, I went to check on her and she was up eating breakfast. I couldn't believe it was the same woman." However, this was an atypical case because the woman "had a healthy liver before the acute injury to it, so we could infuse directly into the liver."
At Nebraska, William C. Culp, MD, assistant professor of radiology, and colleagues have concentrated their efforts on pediatric patients. An 11-year-old girl who had a liver disease that caused excess amounts of bilirubin, a substance produced by the liver, to accumulate in her blood was required to spend 12 to 15 hours a day under ultraviolet lights as treatment, a process called phototherapy. After the cell transplant, her bilirubin level dropped dramatically, and now, "two years later, she is alive and functioning although she still has to spend about four to six hours in phototherapy," says Culp. Moreover, he says, "she came into the hospital, had the transplant, and was discharged the next day. That's not a transplant scenario, that's a tonsillectomy." His team has used liver cell transplants in five patients, two of whom are still alive; three have died. His other surviving patient was an infant who received an infusion at birth. "He was sustained for five months until he could receive an organ transplant," says Culp. The baby is now 1 year old.